Jan. 16 at 4:42 PM
$CAPR considering the triggers and valuation, short term this is a buy with target
$30 and floor
$20, considering cash, recently made institutional funding and the shorted stocks. Risk/reward 30/70
Medium term, assuming FDA approval for DMD, it’s a buy with target
$50 and floor
$30 assuming a shorting below 5%, risk/reward 30/70.
Long term with the exosomes, and considering statements from the Marbans, target is buy-out by BP at
$100 and floor
$10-20 (floor pendant on cash burn and revenue realization). Risk/reward I don’t know. 🤷🏼
I decided to buy more today, making CAPR my second biggest holding.
Maybe needless to say - targets and floors all in my and my Excel sheet’s humble opinion.
